Lung Cancer News
Week Ending May 24, 2021

The Chance to Make a Difference Made Herbst a Lung Cancer Pioneer
“Roy S. Herbst, MD, PhD, was inspired to become an oncologist during his first week as an MD/PhD candidate at Cornell University and The Rockefeller University, thanks in part to Ralph L. Nachman, MD, longtime chair of Weill Department of Medicine at Weill Cornell Medical College.”

New Hope For Early Stage Non-Small Cell Lung Cancer Patients: Immunotherapy After Surgery Lowers Risk of Recurrence
“Use of the cancer immunotherapy treatment atezolizumab after surgery and chemotherapy lowers the risk of tumor recurrence in people with early-stage non-small cell lung cancer (NSCLC), according to new research.”

Johnson & Johnson snares FDA nod for first exon 20-targeted drug in EGFR lung cancer
“Just a few short months after Johnson & Johnson’s Janssen unit sent its targeted non-small cell lung cancer (NSCLC) drug amivantamab to the FDA, the regulator has come back with a green light—a very specific one.”

Edwards Comprehensive Cancer Center offers lung cancer screenings
“HUNTINGTON — The Edwards Comprehensive Cancer Center is now offering a lung cancer screening clinic the third Monday of each month from 8 a.m. to noon. Eligible patients can schedule without a physician referral.”

HonorHealth robot helps detect lung cancer
“HonorHealth’s Scottsdale Shea Medical Center is the first hospital in the state to perform a robotic-assisted bronchoscopy using shape-sensing technology.”

U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer
“SAN FRANCISCO and SUZHOU, China, May 18, 2021 /PRNewswire/ — Innovent Biologics, Inc. (HKEX: 01801) and Eli Lilly and Company (NYSE: LLY) today jointly announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for sintilimab injection in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with nonsquamous non-small cell lung cancer (NSCLC). This is the first U.S. regulatory submission of sintilimab, a PD-1 inhibitor being developed and commercialized under a global collaboration agreement between Innovent and Lilly.”

Video:
Dr. Socinski on the Evolving Paradigm of Targeted Therapy in Lung Cancer
“Mark A. Socinski, MD, executive medical director of the AdventHealth Cancer Institute, discusses the evolving paradigm of targeted therapy in lung cancer.”